(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are ABO GROUP, OREGE, and GENSIGHT BIOLOGICS.

The three biggest losers today are BIOSENIC, BERGENBIO, and LATECOERE.

Winners today

1. ABO GROUP (ABO.BR)

18.64% Price Change

ABO-Group Environment NV, an engineering company, provides geotechnics, soil remediation, energy, and water and waste management solutions in Belgium, the Netherlands, France, and internationally. The company carries out asbestos and soil surveys, laboratory analyses, and demolition inventories; inspections during asbestos removal, decontamination, and demolition projects; and geotechnical tests. It also offers soil investigation services for engineering and consulting projects, as well as soil drilling, probing, and geophysical research services; sonic drilling services; advice on environmental and water management, and subsoil accreditation; geophysical surveys and non-destructive imaging of the subsurface and underground structures; geotechnical, environmental, and geophysical research services; and ground surveys for engineering and consulting projects. In addition, the company provides integrated advice for construction and redevelopment projects; multidisciplinary consultancy in the field of soil, environment, asbestos, due diligence, ecology, and nature-inclusive building; services in the field of explosive remnants of war, drainage advice, archaeology, asphalt and foundations, and various environmental studies; onshore and offshore drilling and sampling services; and geotechnical consultancy services. Further, it operates a laboratory for the analysis of asbestos in materials and air. The company was founded in 1995 and is headquartered in Gent, Belgium.

BEL 20 ended the session with ABO GROUP jumping 18.64% to €7.00 on Monday while BEL 20 dropped 1.69% to €3,596.72.

Earnings Per Share

As for profitability, ABO GROUP has a trailing twelve months EPS of €0.22.

PE Ratio

ABO GROUP has a trailing twelve months price to earnings ratio of 31.82. Meaning, the purchaser of the share is investing €31.82 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ABO GROUP’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for ABO GROUP is 22365 which is 3716.55% above its average volume of 586.

More news about ABO GROUP.

2. OREGE (OREGE.PA)

11.9% Price Change

Orege Société Anonyme designs, develops, operates, manufactures, and markets municipal and industrial sludge, and effluents treatment solutions in France, the United States, Japan, Germany, and the United Kingdom. The company offers SLG solution for conditioning, treating, and recovering municipal and industrial sludge; SLG-F, a combination of SLG conditioning solution; and Flosep for sludge separation and thickening tool. It also provides after-sales, installation and commissioning, operator training, warranty extensions, maintenance, and process line optimization services. The company was incorporated in 2005 and is headquartered in Voisins-Le-Bretonneux, France. Orege Société Anonyme is a subsidiary of Eren Groupe SA.

CAC 40 ended the session with OREGE jumping 11.9% to €0.24 on Monday, following the last session’s downward trend. CAC 40 fell 1.01% to €7,314.05, following the last session’s upward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, OREGE has a trailing twelve months EPS of €-0.12.

Moving Average

OREGE’s worth is way below its 50-day moving average of €0.27 and way under its 200-day moving average of €0.46.

Volatility

OREGE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.72%, a negative 1.34%, and a positive 3.21%.

OREGE’s highest amplitude of average volatility was 1.91% (last week), 3.60% (last month), and 3.21% (last quarter).

More news about OREGE.

3. GENSIGHT BIOLOGICS (SIGHT.PA)

11.57% Price Change

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.

CAC 40 ended the session with GENSIGHT BIOLOGICS jumping 11.57% to €0.96 on Monday, after two consecutive sessions in a row of gains. CAC 40 fell 1.01% to €7,314.05, following the last session’s upward trend on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.69.

Volume

Today’s last reported volume for GENSIGHT BIOLOGICS is 488765 which is 12.08% above its average volume of 436085.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENSIGHT BIOLOGICS’s stock is considered to be oversold (<=20).

More news about GENSIGHT BIOLOGICS.

4. BEAULIEU-AV. CERT (BEAB.BR)

9.78% Price Change

Immo-Beaulieu NV owns and operates real estate properties. The company is based in Brussels, Belgium. Immo-Beaulieu NV operates as a subsidiary of KBC Bank NV.

BEL 20 ended the session with BEAULIEU-AV. CERT rising 9.78% to €4.94 on Monday, following the last session’s downward trend. BEL 20 dropped 1.69% to €3,596.72, after two successive sessions in a row of losses, on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for BEAULIEU-AV. CERT is 508 which is 543.03% above its average volume of 79.

More news about BEAULIEU-AV. CERT.

5. HOTELS DE PARIS (HDP.PA)

9.38% Price Change

Les Hôtels de Paris SA operates and manages hotels in Paris. As of December 31, 2021, it operated 17 hotels in Paris, 1 hotel in St Tropez, and 1 hotel in Marrakech. The company was incorporated in 1992 and is headquartered in Paris, France.

CAC 40 ended the session with HOTELS DE PARIS rising 9.38% to €1.40 on Monday while CAC 40 slid 1.01% to €7,314.05.

Earnings Per Share

As for profitability, HOTELS DE PARIS has a trailing twelve months EPS of €-0.57.

More news about HOTELS DE PARIS.

6. IDI (IDIP.PA)

9.15% Price Change

IDI is a private equity firm specializing in leveraged buyouts, expansion capital, middle market, growth capital, acquisition of significant holdings in listed small and medium companies and secondary private equity portfolios, mezzanine financing, loans senior to senior debt, discounted leveraged buyouts loans in mature companies and through co-investments in pre-IPO financing. Within fund of fund investments, the firm invests in private equity funds and Hedge funds. It seeks to invest in all sectors. The firm primarily seeks to invest in France and European Developed Markets. It generally makes an equity investment between €25 million ($27.61 million) and €70 million ($77.31 million) and invests in companies with an enterprise value ranging between €10 million ($11.04 million) and €300 million ($331.34 million) with the capacity to exceed this limit on a case-by-case basis and invests between €5 million ($5.52 million) and €25 million ($27.61 million) per deal. It seeks to invest in funds with a fund size between $50 million and €300 million ($331.34 million). The firm takes majority and minority stakes in companies with a focus on majority positions in small and medium-sized companies acquiring through leveraged buyouts. The firm mainly invests through its own capital in both direct and fund of funds investments. The firm prefers to invest from its balance sheet. IDI was founded in 1970 and is based in Paris, France with an additional office in Paris, France.

CAC 40 ended the session with IDI jumping 9.15% to €62.00 on Monday while CAC 40 fell 1.01% to €7,314.05.

Earnings Per Share

As for profitability, IDI has a trailing twelve months EPS of €10.31.

PE Ratio

IDI has a trailing twelve months price to earnings ratio of 6.01. Meaning, the purchaser of the share is investing €6.01 for every euro of annual earnings.

Volatility

IDI’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.71%, a negative 0.12%, and a positive 1.11%.

IDI’s highest amplitude of average volatility was 0.71% (last week), 0.96% (last month), and 1.11% (last quarter).

Volume

Today’s last reported volume for IDI is 7732 which is 1625.89% above its average volume of 448.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IDI’s stock is considered to be oversold (<=20).

More news about IDI.

7. REINET INVESTMENTS (REINA.AS)

8.99% Price Change

Reinet Investments S.C.A. operates as a securitization vehicle in Luxembourg. The company, through its subsidiary, Reinet Fund S.C.A., F.I.S., invests in assets. Reinet Investments Manager S.A. operates as a general partner of Reinet Investments S.C.A. The company was formerly known as Richemont S.A. and changed its name to Reinet Investments S.C.A. in October 2008. Reinet Investments S.C.A. was incorporated in 1979 and is based in Luxembourg.

AEX-Index ended the session with REINET INVESTMENTS jumping 8.99% to €20.60 on Monday, following the last session’s downward trend. AEX-Index dropped 0.48% to €768.98, after five consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, REINET INVESTMENTS has a trailing twelve months EPS of €-0.59.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, REINET INVESTMENTS’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for REINET INVESTMENTS is 860 which is 133.69% above its average volume of 368.

Volatility

REINET INVESTMENTS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.40%, a negative 0.48%, and a positive 2.54%.

REINET INVESTMENTS’s highest amplitude of average volatility was 5.01% (last week), 2.93% (last month), and 2.54% (last quarter).

More news about REINET INVESTMENTS.

8. PRODWAYS (PWG.PA)

8.39% Price Change

Prodways Group SA manufactures and sells industrial and professional 3D printers in France and internationally. The company operates in two segments, Systems and Products. It offers machines, such as 3D printing systems that include lost wax, DLP15resin, and laser sintering; and other related premium materials and services, as well as offers 3D design, simulation, and optimization software. The company also provides metal and plastic parts; orthopedic insoles for podiatry application; orthodontic pieces and dental trays, mouthpieces dental application; and hearing aid tips and custom hearing protection products for audiology application. It serves aerospace and defence, healthcare, automotive, consumer goods, and jewellery sectors. Prodways Group SA was founded in 2013 and is headquartered in Paris, France.

CAC 40 ended the session with PRODWAYS rising 8.39% to €1.68 on Monday, after two successive sessions in a row of losses. CAC 40 fell 1.01% to €7,314.05, following the last session’s upward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, PRODWAYS has a trailing twelve months EPS of €0.02.

PE Ratio

PRODWAYS has a trailing twelve months price to earnings ratio of 84. Meaning, the purchaser of the share is investing €84 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.4%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 82.49M for the twelve trailing months.

Volume

Today’s last reported volume for PRODWAYS is 77451 which is 34.65% above its average volume of 57519.

More news about PRODWAYS.

9. HDF (HDF.PA)

8.2% Price Change

Hydrogène de France Société anonyme develops and operates as independent power producer in France and internationally. It operates two hydrogen power plants; and manufactures and sells high power fuel cells. The company was incorporated in 2012 and is based in Lormont, France.

CAC 40 ended the session with HDF rising 8.2% to €16.62 on Monday while CAC 40 fell 1.01% to €7,314.05.

Earnings Per Share

As for profitability, HDF has a trailing twelve months EPS of €-0.25.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HDF’s stock is considered to be oversold (<=20).

More news about HDF.

10. ENVIPCO (ENVI.AS)

8% Price Change

Envipco Holding N.V., together with its subsidiaries, designs, develops, manufactures, and sells or leases reverse vending machines (RVM) for the collection and processing of used beverage containers primarily in the North America and Europe. The company provides technical support, RVM maintenance, and accounting services to the retail stores, bottlers, and distributors for containers redeemed through its machines. It also offers deposit, handling fees, scrap reconciliations, commodity brokerage, clearing house functions, and accounting services. In addition, the company provides materials handling services primarily in the northeastern part of the United States. Envipco Holding N.V. was incorporated in 1998 and is headquartered in Amersfoort, the Netherlands.

AEX-Index ended the session with ENVIPCO jumping 8% to €2.70 on Monday, following the last session’s downward trend. AEX-Index slid 0.48% to €768.98, after five sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, ENVIPCO has a trailing twelve months EPS of €-0.07.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.56%.

Volume

Today’s last reported volume for ENVIPCO is 4529 which is 30.74% above its average volume of 3464.

Sales Growth

ENVIPCO’s sales growth is 6.7% for the ongoing quarter and negative 8.9% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ENVIPCO’s stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

ENVIPCO’s stock is valued at €2.70 at 22:40 EST, way below its 52-week high of €3.65 and way higher than its 52-week low of €2.20.

More news about ENVIPCO.

Losers Today

1. BIOSENIC (BIOS.BR)

-27.14% Price Change

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with BIOSENIC dropping 27.14% to €0.08 on Monday while BEL 20 slid 1.69% to €3,596.72.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.02.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be overbought (>=80).

More news about BIOSENIC.

2. BERGENBIO (BGBIO.OL)

-15.77% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO falling 15.77% to €0.24 on Monday while Oslo Børs Benchmark Index_GI slid 1.13% to €1,231.97.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-2.73.

More news about BERGENBIO.

3. LATECOERE (LAT.PA)

-14.44% Price Change

Latécoère S.A. designs, develops, manufactures, and supports aerostructures and interconnection systems in Europe, the United States, Africa, Asia, and internationally. The company manufactures aircraft structural elements, such as aircraft doors; and fuselage components, such as aircraft sections, tail cones, nose cone fairings, etc. It also offers electrical harnesses and wiring interconnection systems, avionics racks, airborne video equipment and systems, and test benches for the aeronautics, defense, and space sectors, as well as cameras, screens, data transmission solutions. The company was founded in 1917 and is headquartered in Toulouse, France. Latécoère S.A. is a subsidiary of SCP SKN HOLDING I SAS.

CAC 40 ended the session with LATECOERE dropping 14.44% to €0.20 on Monday while CAC 40 fell 1.01% to €7,314.05.

Earnings Per Share

As for profitability, LATECOERE has a trailing twelve months EPS of €0.12.

PE Ratio

LATECOERE has a trailing twelve months price to earnings ratio of 1.65. Meaning, the purchaser of the share is investing €1.65 for every euro of annual earnings.

Volume

Today’s last reported volume for LATECOERE is 1248020 which is 665.37% above its average volume of 163060.

More news about LATECOERE.

4. SARTORIUS STED BIO (DIM.PA)

-12.95% Price Change

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

CAC 40 ended the session with SARTORIUS STED BIO sliding 12.95% to €240.70 on Monday while CAC 40 dropped 1.01% to €7,314.05.

Earnings Per Share

As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €7.8.

PE Ratio

SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 30.86. Meaning, the purchaser of the share is investing €30.86 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SARTORIUS STED BIO’s EBITDA is 7.95.

More news about SARTORIUS STED BIO.

5. DGB GROUP N.V. (DGB.AS)

-12.28% Price Change

DGB Group N.V. invests in, develops, and manages biodiversity and carbon offset, and nature-based projects for businesses and governments in the Netherlands and internationally. The company offers nature-based solutions comprising the management and use of nature for tackling social and environmental challenges; carbon offsetting projects for reducing carbon footprint of companies; and biodiversity protection and ecosystem services. It also provides ESG reporting and tree integration services. The company was formerly known as Verenigde Nederlandse Compagnie N.V. and changed its name to DGB Group N.V. in January 2018. DGB Group N.V. was founded in 1957 and is based in Haarlemmermeer, the Netherlands.

AEX-Index ended the session with DGB GROUP N.V. falling 12.28% to €0.50 on Monday, following the last session’s downward trend. AEX-Index slid 0.48% to €768.98, after five consecutive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, DGB GROUP N.V. has a trailing twelve months EPS of €-0.11.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19%.

Volatility

DGB GROUP N.V.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.89%, a negative 0.16%, and a positive 3.85%.

DGB GROUP N.V.’s highest amplitude of average volatility was 4.49% (last week), 3.47% (last month), and 3.85% (last quarter).

More news about DGB GROUP N.V..

6. ORPEA (ORP.PA)

-11.13% Price Change

ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.

CAC 40 ended the session with ORPEA dropping 11.13% to €2.27 on Monday while CAC 40 dropped 1.01% to €7,314.05.

Earnings Per Share

As for profitability, ORPEA has a trailing twelve months EPS of €-66.14.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ORPEA’s stock is considered to be oversold (<=20).

Volatility

ORPEA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 8.13%, a negative 0.14%, and a positive 4.72%.

ORPEA’s highest amplitude of average volatility was 9.64% (last week), 3.97% (last month), and 4.72% (last quarter).

Volume

Today’s last reported volume for ORPEA is 1312320 which is 14.73% below its average volume of 1539060.

Moving Average

ORPEA’s worth is under its 50-day moving average of €2.39 and way below its 200-day moving average of €6.19.

More news about ORPEA.

7. SODITECH (SEC.PA)

-10.53% Price Change

Soditech SA engages in the integration of mechanical, thermal, and electronic sub-assemblies in space, research, and defense fields in France. It designs structural sub-assemblies and integrates optical and thermal equipment, such as OSRs, SSMs, heaters, and heat pipes; designs and manufactures multi-layer insulation products; and designs, manufactures, and tests space harnesses on instruments or platforms. The company also provides calculation services, such as static, dynamic, thermal, and thermoelastic; designs assembly tools; and designs and produces super insulating multi-layer mattresses for ultra-vacuum areas. In addition, it develops, qualifies, manufactures, and tests embedded cabinets; and designs, assembles, and tests racks and test equipment racks. The company was formerly known as Soditech Ingenierie SA. Soditech SA was founded in 1990 and is headquartered in Aix-en-Provence, France.

CAC 40 ended the session with SODITECH dropping 10.53% to €1.36 on Monday, following the last session’s upward trend. CAC 40 dropped 1.01% to €7,314.05, following the last session’s upward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, SODITECH has a trailing twelve months EPS of €0.14.

PE Ratio

SODITECH has a trailing twelve months price to earnings ratio of 9.71. Meaning, the purchaser of the share is investing €9.71 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.54%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SODITECH’s stock is considered to be oversold (<=20).

Moving Average

SODITECH’s value is way under its 50-day moving average of €1.56 and below its 200-day moving average of €1.49.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.7%, now sitting on 4.59M for the twelve trailing months.

More news about SODITECH.

8. ARTEA (ARTE.PA)

-9.57% Price Change

Artea SA operates as a real estate development company in France. It develops tertiary parks, emblematic projects, urban office buildings, eco-neighborhoods, hotels, shops, and housing projects. The company also generates and supplies electrical power using renewable sources, such as photovoltaics and hydraulics. Artea SA was founded in 2001 and is headquartered in Paris, France.

CAC 40 ended the session with ARTEA falling 9.57% to €20.80 on Monday while CAC 40 slid 1.01% to €7,314.05.

Earnings Per Share

As for profitability, ARTEA has a trailing twelve months EPS of €1.47.

PE Ratio

ARTEA has a trailing twelve months price to earnings ratio of 14.15. Meaning, the purchaser of the share is investing €14.15 for every euro of annual earnings.

Volume

Today’s last reported volume for ARTEA is 3727 which is 1240.65% above its average volume of 278.

More news about ARTEA.

9. BIOCARTIS (BCART.BR)

-7.73% Price Change

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

BEL 20 ended the session with BIOCARTIS sliding 7.73% to €0.37 on Monday while BEL 20 fell 1.69% to €3,596.72.

Earnings Per Share

As for profitability, BIOCARTIS has a trailing twelve months EPS of €-0.8.

More news about BIOCARTIS.

10. FORESTIERE EQUAT. (FORE.PA)

-7.63% Price Change

La Forestière Equatoriale SA, through its step-down subsidiary, Sitarail, operates a railway network that transports people and goods between Côte d'Ivoire to Burkina Faso. The company is based in Puteaux, France.

CAC 40 ended the session with FORESTIERE EQUAT. dropping 7.63% to €605.00 on Monday while CAC 40 dropped 1.01% to €7,314.05.

Earnings Per Share

As for profitability, FORESTIERE EQUAT. has a trailing twelve months EPS of €1.7.

PE Ratio

FORESTIERE EQUAT. has a trailing twelve months price to earnings ratio of 355.88. Meaning, the purchaser of the share is investing €355.88 for every euro of annual earnings.

More news about FORESTIERE EQUAT..

Stay up to date with our winners and losers daily report